diaxonhit (E8T:Berlin)

Last €0.70 EUR

Change Today -0.019 / -2.63%

Volume 0.0

E8T On Other Exchanges

Symbol

Exchange

EN Paris

Berlin

OTC US

As of 2:08 AM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

diaxonhit (E8T) Snapshot

Open €0.70		Previous Close €0.72
Day High €0.70		Day Low €0.70
52 Week High 08/22/12 - €1.13		52 Week Low 05/9/13 - €0.69
Market Cap --		Average Volume 10 Days 0.0
EPS TTM --		Shares Outstanding 0.0
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

E8T:GR Historical Stock Quote
E8T:GR Advanced Stock Chart

Related News

No related news articles were found.

diaxonhit (E8T) Related Businessweek News

No Related Businessweek News Found

diaxonhit (E8T) Details

Diaxonhit develops RNA-based diagnostic tests and small molecule therapeutics for the treatment of Alzheimer's disease (AD) and cancer. Diaxonhit’s technology includes alternative RNA splicing, the process by which a single gene can produce various proteins; Genome-Wide SpliceArray platform (GWSA), a patented microarray design that incorporates a specific probe configuration, enabling an exhaustive monitoring of RNA splice variants in human, mouse, and rat; and Differential Analysis of Transcripts with Alternative Splicing technology for identifying the functionally distinct messenger RNA variants differentially expressed between two biologic samples on a genome-wide basis. It offers AclarusDx, a blood-based test for the diagnosis of AD; EHT Dx14, a breast cancer diagnostic biomarker; and EHT Dx13, a blood-based diagnostic test for prostate cancer. Diaxonhit also develops therapeutic products, such as EHT 0202, a GABAA receptor modulator and a PDE4 inhibitor that is in Phase II clinical trial for the treatment of AD; EHT/AGN 0001, a Phase II clinical trial product for pain and central nervous system indications; EHT/AGN 0002 that is in pre-clinical stage to treat pain and neurodegeneration, as well as for applications in the field of ophthalmology; EHT/AGN 0003, a pre-clinical product for opthalmology and neurodegenerative indications; and EHT 107 that is in preclinical proof-of-concept testing process for applications in the field of oncology. It has strategic collaborations with bioMérieux to develop customized SpliceArray biochips to detect cancer markers in blood samples; and Allergan to discover drugs in the fields of ophthalmology, pain, and neurodegenerative diseases, as well as a research agreement with Pfizer Inc. for the identification of AD biomarkers using the company’s GWSA platform. The company was formerly known as Exonhit S.A. and changed its name to Diaxonhit in December 2012. Diaxonhit was founded in 1997 and is headquartered in Paris, France.

Detailed E8T:GR Company Description...

www.exonhit.com

Founded in 1997

diaxonhit (E8T) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

diaxonhit (E8T) Key Developments

Diaxonhit Presents at BioEquity Europe 2013, May-23-2013 12:00 PM

May 19 13

Diaxonhit Presents at BioEquity Europe 2013, May-23-2013 12:00 PM. Venue: Sheraton Stockholm, Stockholm, Sweden.

Diaxonhit Wins Major Public Tender from the Paris Hospitals (Assistance Publique -- Hôpitaux De Paris)

Apr 23 13

Diaxonhit won through its marketing subsidiary InGen, a major tender from the AGEPS, the Paris Hospitals' (Assistance Publique - Hôpitaux de Paris, AP-HP) central purchasing agency. It involves the supply of tests necessary to perform histocompatibility studies in the context of transplantation activities. The tender covers the next two years and represents potential revenues of up to EUR 5.5 million per year. Histocompatibility studies are necessary to assess compatibility between donors and recipients before transplantation, and to follow-up patients after transplantation in order to monitor potential rejections and to adjust immunosuppressive treatments accordingly.

Diaxonhit Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2012

Mar 28 13

Diaxonhit reported audited consolidated earnings results for the year ended December 31, 2012. For the year, the company reported total revenues of EUR 5,387,000 against EUR 4,993,000 a year ago. Loss from operations was EUR 6,474,000 against EUR 8,095,000 a year ago. Loss before tax was EUR 6,643,000 against EUR 8,202,000 a year ago. Net loss was EUR 5,770,000 against EUR 7,099,000 a year ago. Basic and diluted net loss per share was EUR 0.16 against EUR 0.21 a year ago. Net cash used in operations was EUR 4,447,000 against EUR 6,023,000 a year ago. Purchase of property and equipment was EUR 87,000 against EUR 149,000 a year ago. Pro forma revenue was EUR 28.6 million.